1. Introduction {#s1}
===============

Adverse drug reactions are frequent and remain underestimated causes of acute liver injury that sometimes lead to liver failure, requiring liver transplantation.

High-dose intravenous glucocorticosteroid treatment is one of the most efficient therapeutic options for severe exacerbations of many autoimmune diseases. A review of the literature shows that corticosteroids are not entirely safe for the liver and have been occasionally linked to severe hepatotoxicity \[[@R1]\]\[[@R2]\]\[[@R3]\]. We present a case of a 24-year-old woman who was treated with pulsed methylprednisolone (MT) for multiple sclerosis. MT induced serious liver injury, developing as icteric acute hepatitis with impaired prothrombin synthesis. Hepatotoxicity with prolonged latency appeared after the second MT pulse, and the causal relationship between MT and liver injury was confirmed by unintentional rechallenge test.

2. Case Report {#s2}
==============

A 24-year-old woman with a 3-year history of multiple sclerosis and a primary diagnosis of retrobulbar optic neuritis was referred to our department due to severe acute hepatitis. Three months earlier, she was admitted to the neurology department due to exacerbation of multiple sclerosis. Neurological treatment began with a 6-day course (0.5 g/d) of high-dose intravenous MT, resulting in full recovery of her left arm function. Routine laboratory examinations showed normal liver tests and no autoantibodies in the peripheral blood.

The patient was subsequently switched to beta-1b interferon (Betaferon) treatment and received 2 doses of this drug without any immediate or delayed adverse reactions. After 6 weeks, she developed a subsequent flare of MS, presenting as left-sided limb paralysis. A high-dose intravenous MT pulse (total dose 3.0 g) and 2 injections of Betaferon were given, effecting nearly a full recovery. Four weeks after the MT pulse and 1 week after her last Betaferon dose, the patient developed jaundice with elevated serum levels of aspartate aminotransferase (AST) 900 IU/L (n: 10-31 IU/L), serum alanine aminotransferase (ALT) l740 IU/L (n: 9-34 IU/L), serum alkaline phosphatase 186 IU/L (n: 38-126 IU/L), and serum GGTP 50 IU/L (n: -38 IU/L). The serum bilirubin level was 17.9 mg/dL (n: 0.3-1.2 mg/dL), the direct bilirubin was 16.1 mg/dL, and the prothrombin index was 35.1% (INR 2.52). The serum AFP level was 17.18 ng/mL (n: \< 5 ng/mL). The patient had no history of hepatic disease and denied any use of alcohol. In the previous 6 months, the patient took acetaminophen (used only in a single dose before each Betaferon injection) and oral contraception, which was stopped immediately before the second MT pulse. Serological tests for hepatitis B (including antibodies to HBc), hepatitis C, hepatitis A, and infection with cytomegalovirus (CMV) were negative. Smooth muscle antibodies (SMA) were found in high titers (\> 1:320), and autoantibodies against mitochondria and nuclei were undetected by direct immunofluorescence tests. Her copper urinary excretion was not elevated. An ultrasound abdominal examination showed an intact liver and a normal-sized spleen. No liver biopsy was done due to a low prothrombin level. With a MELD (model for end-stage liver disease) score of 26, the patient was a potential liver transplantation candidate. Fortunately, her liver function improved spontaneously, and the patient was discharged after 3 weeks with normal aminotransferase levels. Considering the potential hepatotoxicity of interferons, we cautiously suspected the Betaferon of inducing liver injury. Three months later, the patient developed a consecutive flare of multiple sclerosis, for which she received a 6-day intravenous MT pulse (total dose 3.0 g) without Betaferon. Her neurological symptoms resolved, but 4 weeks later, she was readmitted to our department with symptoms of acute hepatitis. The serum level of AST was 1488 IU/L, ALT was 1129 IU/L, alkaline phosphatase was 164 IU/L, GGTP was 168 IU/L, prothrombin index was 47% (INR 1.71), and serum bilirubin was 7.3 mg/dL. No drugs, as before, were used to treat the liver disease, and after several weeks, aminotransferases and bilirubin reached reference levels.

3. Discussion {#s3}
=============

We report two serious liver injuries that were related to pulsed MT treatment. The diagnosis was confirmed by the dechallenge-rechallenge relationship between drug administration and hepatitis. Based on a literature review, we identified 12 case reports of corticosteroid-induced hepatotoxicity ([Table](#s3tbl1){ref-type="table"}).

###### Glucocorticosteroid-Induced Hepatotoxicity: Review of 13 Cases

  **Reference**                         **Age/Sex**                                **PrincipalDisease**                       **Type of Steroid**                          **Dose andDuration ofTreatment**                                     **Max. ALT [a](#Fs3tbl1a){ref-type="table-fn"}/AST [a](#Fs3tbl1a){ref-type="table-fn"} , IU/L**   **Max. GGT [a](#Fs3tbl1a){ref-type="table-fn"} /ALP [a](#Fs3tbl1a){ref-type="table-fn"} , IU/L**   **Histology**                                                                                                                                                          **ConcomitantTreatment**                                                  **Follow-up**
  ------------------------------------- ------------------------------------------ ------------------------------------------ -------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  Gerolami *et al.* \[[@R8]\]           27/F [a](#Fs3tbl1a){ref-type="table-fn"}   Crohn disease                              MP [a](#Fs3tbl1a){ref-type="table-fn"}       50 mg daily IV, 2 days                                               7.5xN [a](#Fs3tbl1a){ref-type="table-fn"} /3.2xN                                                  5.1xN/1.8xN                                                                                        Biopsy not done                                                                                                                                                        None                                                                      Normalization of liver tests after MP discontinuation
                                                                                                                              P [a](#Fs3tbl1a){ref-type="table-fn"}        60 mg daily PO, 6 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Nanki *et al.* \[[@R1]\]              53/F                                       Systemic lupus erythematosus               P                                            20 mg daily; PO, (105 days)                                          658/871                                                                                           ND [a](#Fs3tbl1a){ref-type="table-fn"}                                                             Macrovesicular steatosis and mild periportal PMN [a](#Fs3tbl1a){ref-type="table-fn"} infiltration (autopsy)                                                            None                                                                      Death
  Dourakis *et al.* \[[@R2]\]           67/F                                       Dermatomyositis                            P                                            25 mg/t.i.d. IV, (26 days)                                           545/1229                                                                                          2092/467                                                                                           Macrovesicular steatosis and mild portal lymphocyte and PMN infiltration (autopsy)                                                                                     None                                                                      Death
  Weissel *et al.* \[[@R3]\]            71/F                                       Graves ophthalmopathy                      MP + C [a](#Fs3tbl1a){ref-type="table-fn"}   1,0 g daily IV, 3 days- tapering to 0 within 10-14 days; 5 courses   ND                                                                                                ND                                                                                                 Necrosis of liver parenchyme (autopsy)                                                                                                                                 Methimazole started 6 months before MP, continued until the last course   Death
  Salvi *et al.* \[[@R17]\]             43/F                                       Thyroid associated ophthalmopathy          MP                                           7,5 mg/kg IV, every 2 weeks (4 courses)                              1200/850                                                                                          ND                                                                                                 Compatible with autoimmune hepatitis                                                                                                                                   Levothyroxine since 3 years                                               Normalization of liver tests
  Hofstee *et al.*\[[@R18]\]            46/F                                       Multiple sclerosis                         MP                                           0,5 g IV, 5 days                                                     N                                                                                                 ND                                                                                                 Biopsy not done                                                                                                                                                        None                                                                      Normalization of liver tests after MP discontinuation
                                                                                                                                                                           1 g IV, 3 days; 2 years later                                        1095/755                                                                                          156/140                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                           1 g IV, 3 days; 4 years later                                        1600/900                                                                                          ND                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                           1 g IV, 3 days ; 9 years later                                       2350/950                                                                                          ND                                                                                                                                                                                                                                                                                                                                                  
  Das *et al.*\[[@R6]\]                 48/F                                       Multiple clerosis                          MP                                           ND; 3 courses                                                        1650/1430                                                                                         ND/590                                                                                             Preserved architecture with lobular infiltration by lymphocytes, eosinophils and plasma cells                                                                          None                                                                      Normalization of liver tests after MP discontinuation
  Topal *et al.* \[[@R19]\]             47/F                                       Vasculitis of the central nervous system   MP                                           ND; PO, 7 days course                                                2478/1600                                                                                         242/138                                                                                            Biopsy not done                                                                                                                                                        Topiramate; since 1 year and during MP course                             Normalization of liver tests after MP discontinuation
  Rivero Fernandez *et al.* \[[@R4]\]   57/F                                       Multiple sclerosis                         MP                                           1,0 g IV, 3 days                                                     1223/543                                                                                          71/113                                                                                             Acute necrotic hepatitis with ceroid-laden macrophage hyperplasia                                                                                                      None                                                                      Normalization of liver tests 3 months after MP discontinuation
  Takahashi *et al.* \[[@R7]\]          43/F                                       Multiple sclerosis                         MP+P                                         1,0 g IV, 3 days followed by 50 mg/dL PO, for 1 month                Normal                                                                                            Normal                                                                                             Bridging perivenular necrosis with infiltration by inflammatory cells including eosinophils (first biopsy)                                                             None                                                                      
                                                                                                                              MP+P                                         1 g IV, 3 days; 3 years later followed by 50 mg/d PO, plus           1067/1102                                                                                         26/377                                                                                             Bridging perivenular necrosis and interface hepatitis (second biopsy)                                                                                                  6 doses of Interferone beta-1b                                            Normalization of liver tests several months after MP discontinuation. P tapered within 8 months
                                                                                                                              MP                                           1 g IV, 3 days; 5 days later                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Normalization of liver tests 3 months after MP discontinuation. P tapered within 3 months
                                                                                                                              MP                                           1 g IV, 3 days; 13 monts late                                        566/875                                                                                           1785/214                                                                                                                                                                                                                                                                                                                                            
  Loraschi *et al.* \[[@R5]\]           33/M [a](#Fs3tbl1a){ref-type="table-fn"}   Demyelinating encephalopathy               MP                                           Total dose 2,5 g IV, 4 days course                                   1042/349                                                                                          ND/ND                                                                                              Focal liver cell necrosis in acinar zones 2 and 3, monocyte/macrophage infiltration, Kupffer cell hyperplasia, acidophilic bodies and focal microvesicular steatosis   None                                                                      Normalization of liver tests 20 days after MP discontinuation
  Loraschi *et al.* \[[@R5]\]           27/F                                       Retrobulbar optic neuritis                 MP                                           Total dose 4,5 g IV, 6 days course                                   122/39                                                                                            ND/ND                                                                                              Biopsy not done                                                                                                                                                        None                                                                      Normalization of liver tests 4 days after MP discontinuation
  Gutkowski *et al.*                    24/F                                       Multiple sclerosis                         MP                                           Total dose 3,0g IV, 6 days                                           Normal                                                                                            Normal                                                                                             Biopsy not done                                                                                                                                                        None                                                                      
  (present case)                                                                                                                                                           course                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                              MP                                           Total dose 3,0g IV, 6 days course; 6 weeks later                     1740/900                                                                                          186/186                                                                                                                                                                                                                                                                   4 doses of Interferone beta-1b 0,5 g acetami- nophen; 4 times             Normalization of liver tests 3 weeks after MP discontinuation
                                                                                                                              MP                                           Total dose 3,0g IV, 6 days course; 3 months later                    1129/1488                                                                                         168/164                                                                                                                                                                                                                                                                   None                                                                      Normalization of liver tests 6 weeks after MP discontinuation

^a^ Abbereviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, cortisone; F, female; GGT, γ- glutamyltransferase; M, male; MP, methylprednisolone; N, normal; ND, not determined; P, prednisolone; PMN, polymorphonuclear leukocyte.

The clinical course of liver injury varied from asymptomatic hypertransaminasemia to fulminant hepatic failure (3 deaths). In vivo liver histopathology was performed in only 8 cases, showing a large spectrum of lesions. Fernandez et al. reported recurrent acute hepatitis that was characterized by necrosis on histopathological examination, related to intravenous MT that was given on 3 occasions for the management of relapsing multiple sclerosis \[[@R4]\]. Loraschi et al. reported 2 cases of liver damage that was related to high-dose MT therapy for demyelinating disease \[[@R5]\]. The first patient, a 33-year-old man, developed a histologically recognized acute steatohepatitis 5 weeks after last exposure to MT. The second patient, a 27-year-old woman, presented with moderate and asymptomatic augmentation of liver enzymes 6 days after withdrawal of MT. Hypersensitivity reactions were not observed in any patient. Despite their anti-inflammatory and antiallergic properties, corticosteroids also trigger immunoallergic liver injuries. Das et al. reported recurrent liver injuries that occurred 6 weeks and 3 weeks following the second and third course of intravenous MT, respectively, for multiple sclerosis \[[@R6]\]. Liver biopsy showed lobular, primarily perivenular, infiltration with activated lymphocytes, eosinophils, and plasma cells. Moreover, Japanese authors reported the occurrence of autoimmune hepatitis, confirmed by liver histology, in a patient with multiple sclerosis who was treated with MP pulses \[[@R7]\]. In their opinion, autoimmune hepatitis was a consquence of an immune rebound phenomenon after pulsed MP.

The mechanisms of corticosteroid-induced liver injury are unclear and only occasionally are related to reactivation of HBV infection or to the excipient of the MT preparation \[[@R6]\]\[[@R8]\]\[[@R9]\]. Though low doses of corticosteroids are considered safe for the liver, chronic administration of these drugs may be associated with steatosis or steatohepatitis \[[@R2]\]\[[@R10]\]. Intrinsic hepatotoxicity of high doses of corticosteroids is rather unlikely, as serious hepatic injuries that are related to MT occur rarely and are unpredictable. The majority of hepatotoxic drugs causes idiosyncratic reactions. There are two types of idiosyncrasy: immunoallergic and nonallergic (metabolic). The essence of an immunoallergic reaction is a complex interaction between a parent drug or its metabolites with immunologically competent cells, leading to necrosis and apoptosis of hepatocytes. Released cytokines additionally damage liver cells or have immune-modulating effects \[[@R11]\]. In metabolic idiosyncrasy, the liver injury is caused by aberrant hepatic metabolism, leading to overproduction of reactive metabolites from a parent compound. In general, idiosyncratic drug-induced hepatotoxicity is considered to be unpredictable and dose-independent \[[@R11]\]; however, it has been suggested that there is dose-dependency for drugs that are extensively metabolized in the liver \[[@R12]\]. MT is metabolized by cytochrome P450 3A4 (CYP3A4), and its metabolites undergo renal elimination.

In our patient, we did not observe any systemic hypersensitivity symptoms before or during liver injury. After two exposures to MT, the hepatitis episodes appeared 4 weeks after drug withdrawal. In metabolic idiosyncrasy, the latency periods vary considerably from days to months, and adverse reactions can occur even several weeks after drug discontinuation. Such examples are not common but have been reported for some antibiotics, such as amoxicillin clavulanate, midecamycin, trovafloxacin, and flucloxacilline \[[@R13]\]\[[@R14]\]\[[@R15]\]\[[@R16]\]. The duration of anti-inflammatory effects after a single intramuscular injection of 40-80 mg MT ranges from 4 days to 8 days. Thus, it seems unlikely that chemically active metabolites damage hepatocytes 4 weeks after drug discontinuation. Rather, this scenario suggests a delayed immune response to the metabolite that is bound to the host protein and successive presentation as a neoantigen to the immune cells following the death of hepatocytes. The appearance of SMA following exposure to MT might be a feature of the immunological response.

4. Conclusion {#s4}
=============

MT pulses are increasingly used by neurologists, rheumatologists, and endocrinologists to treat various autoimmune diseases. The general awareness of the potential hepatotoxicity of high-dose corticosteroids is very low. Corticosteroid-induced liver injury may occur as acute hepatitis that develops several weeks after short-term drug exposure. We therefore feel that MT should be placed on the list of hepatotoxic drugs and that patients who receive corticosteroid pulses should be screened for potential liver injury.
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